Evidence map›Paper›PMID 41886139›Full record

ArticleJournal of cancer survivorship : research and practice2026

Association of neuropathy, sarcopenia and physical function in acute lymphoblastic leukemia survivors with chemotherapy alone.

Martin Kaj Fridh, Mengqi Xing, Sedigheh Mirzaei, David Mizrahi, Hanne Bækgaard Larsen, Stephanie B Dixon, Nicholas S Phillips, Kevin R Krull, Hiroto Inaba, Ching-Hon Pui and 5 more

Abstract read
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Martin Kaj FridhDepartment of Pediatrics and Adolescent Medicine, The Juliane Marie Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. martin.kaj.fridh@regionh.dk.
Mengqi XingDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Sedigheh MirzaeiDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
David MizrahiThe Daffodil Centre, The University of Sydney, Sydney, Australia.
Hanne Bækgaard LarsenFaculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Stephanie B DixonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS-735, Memphis, 38105, TN, USA.
Nicholas S PhillipsDepartment of Psychology and Biobehavioral Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Kevin R KrullDepartment of Psychology and Biobehavioral Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Hiroto InabaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Seth E KarolDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Angela DelaneyDepartment of Endocrinology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Sue C KasteDepartment of Radiology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Melissa M HudsonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS-735, Memphis, 38105, TN, USA.
Kirsten K NessDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS-735, Memphis, 38105, TN, USA. kiri.ness@stjude.org.

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
The St. Jude Lifetime Cohort StudyU01CA301480 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MELISSA M HUDSON, Kirsten Kimberlie Ness · 2025 to 2026
$2.1M
NCI NIH HHS P30 CA021765NCI NIH HHS U01 CA195547NCI NIH HHS U01 CA301480
6 · The paper itself

Abstract

backgroundDespite excellent survival and elimination of cranial radiation, patients treated for acute lymphoblastic leukemia (ALL) in childhood remain at increased risk for chronic conditions, including peripheral neuropathy and sarcopenia. This study aimed to evaluate the association between peripheral neuropathy and sarcopenia in survivors of childhood ALL without prior cranial radiation exposure. Additionally, we explore the effects of neuropathy and sarcopenia on physical function and exercise behavior.

methodsWe included survivors of childhood ALL diagnosed between 1962 and 2012, aged ≥18 years without a history of cranial radiation from the St. Jude Lifetime Cohort Study (SJLIFE). Peripheral neuropathy was assessed using the Modified Total Neuropathy Score (mTNS). Sarcopenia was defined by low muscle mass (dual X-ray absorptiometry) and muscle weakness, with muscle strength assessed using hand grip and quadriceps strength tests. Physical function was evaluated with the Timed-Up-and-Go test and a 50-foot walk test. Physical activity was self-reported via the NHANES Physical Activity Questionnaire. Statistical analyses, including modified Poisson regression, were performed to examine associations.

resultsAmong 537 survivors (median age: 28 years, range 18-52), 31.7% had peripheral neuropathy, 19.0% had reduced muscle strength, and 21.6% had reduced relative lean muscle mass. Neuropathy was significantly associated with impaired gait speed (RR: 1.31, 95% CI 1.01 to 1.7). Sarcopenia, particularly impaired muscle strength, was associated with impaired mobility (RR: 2.99, 95% CI 1.91 to 4.68), gait speed (RR: 1.45, 95% CI 1.06 to 1.97), and <150 min/week of moderate or vigorous physical activity (RR 1.43, 95% CI 1.04 to 1.95).

conclusionPeripheral neuropathy and sarcopenia significantly impact physical function in childhood ALL survivors, with impaired muscle strength emerging as a key determinant of mobility limitations. These findings emphasize the importance of targeted interventions, particularly strengthening exercise, to improve functional outcomes in this vulnerable population. Future research should focus on developing evidence-based rehabilitation strategies to enhance long-term survivorship care. CLINICAL IMPACT: Evaluation of muscle strength, lean mass, and gait performance may facilitate early identification of survivors at risk for functional decline and premature aging.

Indexed as

Acute lymphoblastic leukemiaNeuropathyPhysical functionSarcopeniaSurvivors

Identifiers

PMID41886139
PMCPMC13142173

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.